| Document |
Document Title |
|
WO/2023/108053A1 |
Disclosed herein are compositions for and methods of treating and/or preventing hereditary aortopathies, treating and/or preventing aortic aneurysms, reducing the need for surgical intervention, slowing and/or inhibiting disease progress...
|
|
WO/2023/104021A1 |
A metabolic checkpoint-based human serum albumin nano-drug (IDNPs), and a preparation method therefor and an application thereof. A prodrug molecule IDOi-DON obtained by coupling an indoleamine-2,3-dioxygenase inhibitor (IDOi) and a meta...
|
|
WO/2023/104027A1 |
The present invention provides a yeast immune micro-nano biorobot loaded with blood coagulation drugs, a preparation method therefor and an application thereof. The yeast immune micro-nano biorobot loaded with blood coagulation drugs com...
|
|
WO/2023/104125A1 |
Provided in the present invention are a biomimetic bioengine yeast micro/nanorobot and preparation method therefor. The biomimetic bioengine yeast micro/nanorobot comprises a yeast cell wall having a capsule-shaped structure, drug-loaded...
|
|
WO/2023/106963A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form V of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxol...
|
|
WO/2023/107712A1 |
The present disclosure provides methods of treating or preventing various conditions, diseases, and disorders (e.g., cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID-19, and myeloablation) in a subject in ne...
|
|
WO/2023/104056A1 |
Provided in the present invention are a yeast bionic immune micro-nano biological robot, and a preparation method therefor and the use thereof. The yeast bionic immune micro-nano biological robot comprises a yeast cell wall microcapsule,...
|
|
WO/2023/104137A1 |
Disclosed are a method for preparing tumor antigen-responsive living cellular nano backpacks and the use thereof. The loading of immune lymphocyte to reduction-responsive albumin nano backpacks is achieved by means of bio-orthogonal coup...
|
|
WO/2023/104058A1 |
The present invention provides a macrophage-based living cell drug-loading system, comprising living cells and drug-loading yeast bionic micro-motors located inside the living cells, wherein the living cells are macrophages, and each dru...
|
|
WO/2023/106964A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form IV of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxo...
|
|
WO/2023/097422A1 |
Disclosed in the present invention is an application of lysine(K)‑specific demethylase 6B (KDM6B) in regulating and controlling the function of a mesenchymal stem cell. WDR5 is a co-binding protein for negatively regulating and control...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/097980A1 |
Use of a cationic polymer in the preparation of a drug for preventing or treating diseases caused by a toxin produced by intestinal microorganisms or diseases caused by a novel coronavirus infection. The chronic inflammations and various...
|
|
WO/2023/098273A1 |
Disclosed are a target for screening a drug for inhibiting the intestinal fatty acid intake and preventing fatty liver, and the use thereof. According to a knockout mouse experiment, provided in the present invention are a target Soat2 (...
|
|
WO/2023/102091A2 |
The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.
|
|
WO/2023/100745A1 |
The present disclosure relates to: a composition for inducing germinal center migration of activated B-cells, the composition containing a substance that induces expression of CD11b in B-cells; a method for manufacturing the composition;...
|
|
WO/2023/100925A1 |
Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated. The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell divi...
|
|
WO/2023/100691A1 |
The present disclosure relates to providing a substance and a composition that promote the proliferation of epidermal stem cells and are effective in improving wrinkles and barrier function from the viewpoint of maintaining or improving ...
|
|
WO/2023/100977A1 |
The present invention addresses the problem of revealing a symptom onset mechanism of allergies in which bacteria belonging to the family Lachnospiraceae including Ruminococcus gnavus (R. gnavus) which is an enteric bacterium is involved...
|
|
WO/2023/100134A1 |
This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination w...
|
|
WO/2023/100131A1 |
The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent...
|
|
WO/2023/100829A1 |
The present invention provides a novel MuSK antibody. The present invention provides a molecule which binds to a target antigen, and is characterized by comprising a region that binds to the target antigen, a first peptide that recogni...
|
|
WO/2023/102018A1 |
The present disclosure provides compositions, systems, pre-filled delivery devices, and methods for developing injectable compositions useful for in situ forming solid depots for the sustained release of non-steroidal anti-inflammatory d...
|
|
WO/2023/100070A1 |
The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising adminis...
|
|
WO/2023/095929A1 |
Provided are: an agent for treatment of malignant tumors, the agent being characterized by containing an immune checkpoint inhibitor and by being used in combination with a boron neutron capture therapy; (i) an immune checkpoint inhibito...
|
|
WO/2023/092988A1 |
An application of a trihalophenol inhibitor in preparation of a drug for regulating and controlling the anti-infection capability of macrophages. Trihalophenol DBPs can cause damage of anti-infection immunity of mammals by interfering wi...
|
|
WO/2023/094580A1 |
The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and/or pter...
|
|
WO/2023/093763A1 |
Provided are systems and methods for immunotherapies. Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proli...
|
|
WO/2023/096448A1 |
The present invention relates to a use of Obatoclax in treating metabolic and fibrotic diseases, and more specifically, to a novel use of Obatoclax in preventing or treating metabolic and fibrotic diseases, wherein Obatoclax exhibits the...
|
|
WO/2023/093840A1 |
This disclosure relates to the use of Wee1 kinase inhibitors in the treatment of cancer. In particular, the disclosure provides the use of Wee1 kinase inhibitors in the preparation of drugs for the treatment of cancers with FBXW7 or CHD4...
|
|
WO/2023/093807A1 |
The present invention relates to a compound and method for treating liver diseases.
|
|
WO/2023/095860A1 |
The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substitute...
|
|
WO/2023/091901A1 |
Described herein are methods and compositions for treating or reducing the likelihood of a subject developing a pancreatic disease or disorder or keloids. In one embodiment, the method comprises administering a therapeutically effective ...
|
|
WO/2023/088464A1 |
The present invention relates to the field of biomedicine, and particularly relates to a CD300LD inhibitor and a use thereof in preparation of a tumor immunotherapy product. According to the present invention, the CD300LD inhibitor adjus...
|
|
WO/2023/090425A1 |
The present invention addresses the problem of providing an anti-inflammation agent for intraocular applications, which can prevent an excessive inflammation in an interocular tissue. The anti-inflammation agent comprises an ERK-activati...
|
|
WO/2023/088356A1 |
An application of a receptor-interacting protein 2 (RIP2) inhibitor combined with a chemotherapy drug, particularly, an application of a RIP2 inhibitor combined with a chemotherapy drug in preparation of a drug for treating and/or preven...
|
|
WO/2023/087421A1 |
Provided is the use of polymerized hemoglobin in the preparation of a drug for treating an ischemic stroke. The drug is a hemoglobin oxygen carrier and is also a colloid solution, and the particle size of the polymerized hemoglobin is on...
|
|
WO/2023/090728A1 |
The present invention relates to a compound for inhibiting tankyrase, and medical use thereof. Since the compound according to the present invention inhibits the activity of enzyme tankyrase (TNKS), inhibits target β-catenin gene expres...
|
|
WO/2023/091625A1 |
Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.
|
|
WO/2023/088415A1 |
An Andrias davidianus skin secretion hydrolysate, and a preparation method therefor and an application thereof The preparation method comprises: S1: mixing a disulfide bond reducing agent and a first solvent to obtain a second solvent; S...
|
|
WO/2023/088235A1 |
The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
|
|
WO/2023/090662A1 |
In the present invention, calsequestrin 1 (CASQ1) binds to STIM2 through the C1 (N-terminal 92 amino acid sequence) site of CASQ1 and the expression of CASQ1 or the C1 site thereof (CASQ1-STIM2 binding) is identified to lower store-opera...
|
|
WO/2023/089132A1 |
The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and wa...
|
|
WO/2023/089032A1 |
The invention relates to methods and pharmaceutical compositions for the treatment of cancer, particularly BRCA-associated cancer and chemo-resistance BRCA-associated cancer. The inventors investigated the role of NMNAT1 in cancer, parti...
|
|
WO/2023/090850A1 |
The present invention provides a pharmaceutical composition for preventing or treating a cancer, which comprises a combination of a first compartment comprising a derivative having a certain cyclohexyl-ethylene-amino-heteroaryl moiety or...
|
|
WO/2023/092046A1 |
Disclosed herein is a method for treating and/or minimize injection site reactions (ISRs) and/or preventing severe ISRs in a subject in need thereof by admixing, co-formulating or co-administering a steroid composition. In some embodimen...
|
|
WO/2023/092112A1 |
The present disclosure provides methods of treating a subject having a headache or a migraine or preventing a subject from developing a headache or a migraine by administering an Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) inh...
|
|
WO/2023/090903A1 |
The present application relates to a composition which is for preventing or treating cancer or inflammation and comprises a novel Leuconostoc mesenteroides strain, a culture thereof, or an ingredient derived therefrom.
|
|
WO/2023/091905A1 |
Disclosed herein are targeted extracellular vesicles (e.g., exosomes, ectosomes, microvesicles/microparticles, apoptotic bodies, macrovesicles) and targeted micelles, as well as methods of using a targeted extracellular vesicle or a targ...
|
|
WO/2023/091553A1 |
The disclosure provides an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof, for use in methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed ...
|
